B. Metzler seel. Sohn & Co. Holding AG Invests $3.16 Million in Hologic, Inc. (NASDAQ:HOLX)

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 38,838 shares of the medical equipment provider's stock, valued at approximately $3,164,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its stake in Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock valued at $490,931,000 after buying an additional 2,753,016 shares during the last quarter. Swedbank AB purchased a new stake in Hologic during the first quarter valued at $120,827,000. Black Creek Investment Management Inc. lifted its holdings in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after acquiring an additional 885,524 shares during the period. Mackenzie Financial Corp lifted its holdings in Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock valued at $66,506,000 after acquiring an additional 815,960 shares during the period. Finally, Marshall Wace LLP purchased a new position in Hologic in the second quarter worth about $39,427,000. Institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $78.04 on Thursday. The stock has a 50-day moving average price of $80.52 and a 200 day moving average price of $78.30. The stock has a market capitalization of $18.13 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.89 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Finally, Stephens reissued an "overweight" rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.